Bradley J. Monk, MD, FACOG, FACS
Currently, standard frontline treatment for patients with recurrent ovarian cancer is a chemotherapy regimen of carboplatin and paclitaxel. Beyond the success with PARP inhibitors, though, novel strategies are under investigation, including an antibody-drug conjugate and a gemcitabine analog, said Bradley J. Monk, MD, FACOG, FACS.
The answer to that, according to Monk, is immunotherapy and antibody–drug conjugates. During his presentation on recurrent disease, Monk homed in on the trials of 2 agents, mirvetuximab soravtansine (IMGN853) and a first-in-class nucleotide analogue NUC-1031 (Acelarin).
There are 2 ways that folate can get into the cell, Monk explained. One is through a receptor, and the other is through a channel. The channel transports most of the folate, but the receptor is highly expressed in ovarian cancer, he said. This means that making an antibody that will bind to the overexpressed folate receptor on the ovarian cancer cell can be effective.
... to read the full story